Evidence map›Paper›PMID 24740301›Full record

ArticlePloS one2014

Interleukin-7 and Toll-like receptor 7 induce synergistic B cell and T cell activation.

Angela Bikker, Aike A Kruize, Kim M G van der Wurff-Jacobs, Rogier P Peters, Marije Kleinjan, Frank Redegeld, Wilco de Jager, Floris P J G Lafeber, Joël A G van Roon

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Deep Phenotyping of CD11cFrontiers in immunology · 2021
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Angela BikkerDepartment of Rheumatology & Clinical Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Aike A KruizeDepartment of Rheumatology & Clinical Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Kim M G van der Wurff-JacobsDepartment of Rheumatology & Clinical Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Rogier P PetersDepartment of Rheumatology & Clinical Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Marije KleinjanDepartment of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
Frank RedegeldDepartment of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
Wilco de JagerDepartment of Pediatric Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Floris P J G LafeberDepartment of Rheumatology & Clinical Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Joël A G van RoonDepartment of Rheumatology & Clinical Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
University Medical Center Utrecht · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the potential synergy of IL-7-driven T cell-dependent and TLR7-mediated B cell activation and to assess the additive effects of monocyte/macrophages in this respect.

methodsIsolated CD19 B cells and CD4 T cells from healthy donors were co-cultured with TLR7 agonist (TLR7A, Gardiquimod), IL-7, or their combination with or without CD14 monocytes/macrophages (T/B/mono; 1 : 1 : 0,1). Proliferation was measured using 3H-thymidine incorporation and Ki67 expression. Activation marker (CD19, HLA-DR, CD25) expression was measured by FACS analysis. Immunoglobulins were measured by ELISA and release of cytokines was measured by Luminex assay.

resultsTLR7-induced B cell activation was not associated with T cell activation. IL-7-induced T cell activation alone and together with TLR7A synergistically increased numbers of both proliferating (Ki67+) B cells and T cells, which was further increased in the presence of monocytes/macrophages. This was associated by up regulation of activation markers on B cells and T cells. Additive or synergistic induction of production of immunoglobulins by TLR7 and IL-7 was associated by synergistic induction of T cell cytokines (IFNγ, IL-17A, IL-22), which was only evident in the presence of monocytes/macrophages.

conclusionsIL-7-induced CD4 T cell activation and TLR7-induced B cell activation synergistically induce T helper cell cytokine and B cell immunoglobulin production, which is critically dependent on monocytes/macrophages. Our results indicate that previously described increased expression of IL-7 and TLR7 together with increased numbers of macrophages at sites of inflammation in autoimmune diseases like RA and pSS significantly contributes to enhanced lymphocyte activation.

Indexed as

AminoquinolinesAntigens, CD19B-LymphocytesCD4-Positive T-LymphocytesCell ProliferationCells, CulturedCoculture TechniquesCytokinesEnzyme-Linked Immunosorbent AssayFlow CytometryHLA-DR AntigensHumansImidazolesImmunoglobulin GImmunoglobulin MInterleukin-7AminoquinolinesAntigens, CD19CytokinesgardiquimodHLA-DR AntigensImidazolesImmunoglobulin GImmunoglobulin MInterleukin-7Ki-67 AntigenToll-Like Receptor 7

Identifiers

PMID24740301
PMCPMC3989236
OpenAlexW1969711747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.